VRI probiotics inhibit inflammation
09 March, 2005 by Melissa TrudingerVRI Biomedical (ASX:VRI) has reported success in the first stage of a drug discovery program to identify the molecule responsible for the anti-inflammatory effects of its probiotic bacterial strain PCC.
Metabolic confirms dosing study
08 March, 2005 by Melissa TrudingerMetabolic Pharmaceuticals (ASX:MBP) has confirmed that it will perform a further dosing study of its anti-obesity drug AOD9604, but a final decision on the protocol must await the outcome of partnering discussions
Stirling goes back to the drawing board
07 March, 2005 by Melissa TrudingerStirling Products (ASX:STI) will extend its proof-of-concept studies to include a more direct delivery method after analysis of levels of its beta agonist ST810, a single enantiomer form of salbutamol, in the bloodstream of merino lambs showed that the growth promoter was not getting into the bloodstream.
In brief: Epitan; Genesis R&D
07 March, 2005 by Melissa TrudingerEpitan (ASX:EPT) has been given the green light to go ahead with its Phase II study evaluating the photo-protective effects of its sustained release formulation of Melanotan, after receiving ethics approval from the Royal Prince Alfred Hospital in Sydney.
Cochlear acquires Swedish hearing implant company
04 March, 2005 by Melissa TrudingerCochlear (ASX:COH) has signed an agreement to acquire Swedish hearing implant company Entific Medical Systems, owned by Swiss-Swedish group Nobel Biocare for SEK1,050 million (approximately AUD$195 million) to be paid with around AUD$40 million in cash and the remainder as bank debt to be raised in a combination of Euros and US dollars.
In brief: Rockeby, C3, Heartware
04 March, 2005 by Staff WritersRockeby Biomed Limited (ASX:RBY) is poised to launch its Candia5 candidiasis diagnostic in Europe, having received ISO certification and CE Mark approval for the product.
Phylogica launches IPO, touts protein libraries
04 March, 2005 by Melissa TrudingerPerth company Phylogica has launched its IPO and is hoping to raise AUD$5 million from the sale of 25 million shares at $0.20 to support the preclinical development of three lead candidates -- including an asthma vaccine -- and its protein libraries.
FDA officials consider longer trials; promise early warnings
04 March, 2005 by Staff WritersUS regulators are moving to get drug safety warnings to patients and physicians earlier, which should limit prescribing and cut the number of dangerous side effects, a top US Food and Drug Administration official has told the United States congress.
Qld aims to be pharma state
03 March, 2005 by Graeme O'NeillPremier Peter Beattie continues to lay the foundations for his ambition to make Queensland the nation's biotech-pharma mecca, by launching a new report on the state's growing pharmaceutical industry.
LCT upgrades technology through deal with Theracyte
03 March, 2005 by Graeme O'NeillKiwi-born cell-therapy company Living Cell Technologies (ASX:LCT) is to acquire the technology and IP rights of a potential competitor, US-based cell-therapy company Theracyte.
Patents won't save our genetic resources: report
03 March, 2005 by Melissa TrudingerA report by Monash University's Australian APEC Study Centre has cast doubt on the ability of patent-based regimes to provide enough incentive to protect the world's genetic resources.
Cash up for grabs from NZ fund
03 March, 2005 by Melissa TrudingerThe NZ$12 million Australia New Zealand Biotechnology Partnership Fund has awarded NZ$6.76 million in its first round of grants to trans-Tasman biotechnology projects.
Pharmas move towards full disclosure
03 March, 2005 by Mark D. UehlingThe 2005 Clinical Trial Congress explored what may be the most private area of any pharmaceutical company's anatomy: its unpublished clinical trials. Must the pharmaceutical industry reveal more? Or should it ride out the cries of journal editors who demand that it disclose the designs and results of trials? That question will roil government regulators, journal editors, and companies of all sizes this year.
Bresagen rights issue cancelled
02 March, 2005 by Melissa TrudingerBresagen (ASX:BGN) has cancelled its non-renounceable rights issue which the company had hoped would raise AUD$8.8 million, citing failure to meet the minimum subscription of $2 million.
Appointments: Pharmaxis, Bone Medical
02 March, 2005 by Melissa TrudingerSydney-based Pharmaxis (ASX:PXS) has appointed former Structural Genomix VP of drug discovery Ian Macdonald to the position of chief technical officer.
